BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 8780463)

  • 1. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.
    Ismail M; Metwally A; Farghaly A; Bruce J; Tao LF; Bennett JL
    Am J Trop Med Hyg; 1996 Aug; 55(2):214-8. PubMed ID: 8780463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.
    Ismail M; Botros S; Metwally A; William S; Farghally A; Tao LF; Day TA; Bennett JL
    Am J Trop Med Hyg; 1999 Jun; 60(6):932-5. PubMed ID: 10403323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection.
    Radwan A; El-Lakkany NM; William S; El-Feky GS; Al-Shorbagy MY; Saleh S; Botros S
    Parasit Vectors; 2019 Jun; 12(1):304. PubMed ID: 31208446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
    Lotfy WM; Hishmat MG; El Nashar AS; Abu El Einin HM
    Pharm Biol; 2015 Aug; 53(8):1214-9. PubMed ID: 25609146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.
    Fallon PG; Doenhoff MJ
    Am J Trop Med Hyg; 1994 Jul; 51(1):83-8. PubMed ID: 8059919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt.
    Botros S; Sayed H; Amer N; El-Ghannam M; Bennett JL; Day TA
    Int J Parasitol; 2005 Jun; 35(7):787-91. PubMed ID: 15925597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory induced resistance to praziquantel in experimental schistosomiasis.
    Ismail MM; Taha SA; Farghaly AM; el-Azony AS
    J Egypt Soc Parasitol; 1994 Dec; 24(3):685-95. PubMed ID: 7844435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of Schistosoma mansoni to praziquantel: is there a problem?
    Doenhoff MJ; Kusel JR; Coles GC; Cioli D
    Trans R Soc Trop Med Hyg; 2002; 96(5):465-9. PubMed ID: 12474468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice.
    Tanaka M; Ohmae H; Utsunomiya H; Nara T; Irie Y; Yasuraoka K
    Am J Trop Med Hyg; 1989 Aug; 41(2):198-203. PubMed ID: 2505624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered response of strain of Schistosoma mansoni to oxamniquine and praziquantel.
    Bonesso-Sabadini PI; de Souza Dias LC
    Mem Inst Oswaldo Cruz; 2002 Apr; 97(3):381-5. PubMed ID: 12048569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.
    El-Feky GS; Mohamed WS; Nasr HE; El-Lakkany NM; Seif El-Din SH; Botros SS
    Antimicrob Agents Chemother; 2015; 59(6):3501-8. PubMed ID: 25845870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure.
    Sabra AN; Botros SS
    J Parasitol; 2008 Apr; 94(2):537-41. PubMed ID: 18564758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt.
    Barakat R; El Morshedy H
    Parasitology; 2011 Apr; 138(4):440-6. PubMed ID: 21078223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and bioavailability of different praziquantel brands.
    Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
    Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether.
    El-Bassiouni EA; Helmy MH; Saad EI; El-Nabi Kamel MA; Abdel-Meguid E; Hussein HS
    Br J Biomed Sci; 2007; 64(4):168-74. PubMed ID: 18236739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.
    Liang YS; Coles GC; Dai JR; Zhu YC; Doenhoff MJ
    J Helminthol; 2002 Dec; 76(4):327-33. PubMed ID: 12498638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to praziquantel, effect of drug pressure and stability test.
    Ismail MM; Farghaly AM; Dyab AK; Afify HA; el-Shafei MA
    J Egypt Soc Parasitol; 2002 Aug; 32(2):589-600. PubMed ID: 12214936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni.
    Mohammad OS; Hussein HM; Abdel-Sayed SW; Mohamed GA; Shehata MAS
    Parasitol Res; 2024 May; 123(5):215. PubMed ID: 38771511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni.
    el-Lakkany NM; el-Din SH; Sabra AN; Hammam OA
    Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):814-22. PubMed ID: 22124553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antischistosomal effects of praziquantel, its alkaline hydrolysis and sun decomposed products on experimentally S. mansoni infected albino mice. (A) Efficacy assessment based on clinicopathological findings.
    Suleiman MI; Akarim EI; Ibrahim KE; Saad AM; Mohammed AE; Ahmed BM; Sulaiman SM
    J Egypt Soc Parasitol; 2004 Apr; 34(1):131-42. PubMed ID: 15143740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.